In this white paper, Globant discusses a specific application of AI in drug discovery and virtual screening.
Artificial intelligence (AI) is a technology well-suited for dealing with large amounts of information and has long been considered a promising tool in drug discovery. It has made steady inroads in the field in the last decade by improving the probability of success and bringing greater precision, speed, and cost-efficiency to a process notorious for high failure rates, very long timelines, and high costs.
AI can deliver value in drug discovery in various ways, including discovering new indications for existing drugs, identifying new drug candidates, and designing new chemical compounds that could enable novel treatments.
Download our white paper to learn more.
Discover more about Globant
We are a digitally native company that helps organizations reinvent themselves and unleash their potential. We are the place where innovation, design and engineering meet scale. We are more than 27,000 Globers present in 25 countries in 5 continents working for companies like Google, Electronic Arts and Santander, among others. We were named a Worldwide Leader in CX Improvement Services by IDC MarketScape report. We were also featured as a business case study at Harvard, MIT, and Stanford. We are a member of The Green Software Foundation (GSF) and the Cybersecurity Tech Accord. For more information, visit www.globant.com
